The Newsroom

Investigations  /  04.12.2021

Investigation of CytoDyn Inc.

You Have Legal Options

CytoDyn Inc. (CYDY) Misled Shareholders About the Viability of its Drug for the Treatment of COVID-19

CytoDyn is a biotech company that – prior to the COVID-19 pandemic – was focusing on the development and commercialization of the drug “Leronlimab” for the treatment of patients with HIV.  Since the beginning of the COVID-19 pandemic, CytoDyn has aggressively touted Leronlimab as a treatment for COVID-19, including that it had sought emergency use authorization (“EUA”) from the U.S. Federal Drug Administration (“FDA”) and planned to move forward with Operation Warp Speed.  This, in turn, caused CytoDyn’s stock price to skyrocket.  Having traded at less than $1 per share throughout 2019, CytoDyn’s stock reached its peak on June 30, 2020, trading at over $10 per share.  While the stock price was artificially inflated, insiders dumped millions of shares for almost $26 million.

Thereafter, the Company’s scheme began to unravel.  On August 26, 2020, The Wall Street Journal reported that CytoDyn was not being considered for Operation Warp Speed.  On September 16, 2020, CytoDyn’s CEO admitted the Company had not actually made the request for EUA from the FDA.  Beginning on March 5, 2021, the Company revealed that the primary endpoints of its Phase IIb/III data on Leronlimab was not statistically significant.  On this news, CytoDyn’s stock plummeted over several trading days, to close at just $2.35 on March 9. 2021.

If you purchased shares of CytoDyn, Inc. (CYDY) between March 27, 2020 and March 9, 2021, you have until May 17, 2021, to ask the court to appoint you lead plaintiff for the class.

All representation is on a contingency fee basis.  Shareholders pay no fees or expenses.

  • If you would like more information about your rights and potential remedies please send us a message. 

  • Please Note: Neither the submission to nor the receipt of information by Robbins LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.

How can we help you?

CONTACT US TODAY | 1 800 350 6003 or [email protected]

Tell us your concerns